子宫内膜增殖症保守治疗的疗效观察Efficacy of different therapies in treatment of endometrial hyperplasia
孙清;杨兴升;李玲;何淼龙;吴倩;王秀珍;
摘要(Abstract)：
目的:观察并评价不同保守治疗方案对子宫内膜复杂性增生(CH)及非典型增生(AH)的治疗效果、并发症及患者可接受性。方法:前瞻性研究2009年1月至2012年12月在山东大学齐鲁医院门诊及住院收治的50岁以下、病理结果证实为CH的患者116例,将患者随机分为3组,分别接受口服孕激素(A组)、口服避孕药(B组)或LNG-IUS(C组)治疗;AH的患者共90例,将其随机分为2组,分别接受口服孕激素或GnRH-a治疗。每3个月取子宫内膜行病理检查,随访观察患者治疗后的病理缓解率及不良反应。结果:(1)CH患者:治疗6个月时,口服孕激素治疗组、口服避孕药治疗组、LNGIUS组的病理缓解率分别为77.5%、73.7%和94.7%(P=0.039),治疗期间体重增加的发生率依次为42.5%、7.9%和2.6%(P=0.001),突破性出血发生率分别为15.0%、5.2%和26.3%(P=0.023),恶心呕吐症状发生率分别为7.5%、5.2%和2.6%(P=0.624)。(2)AH患者:治疗6个月时,口服孕激素治疗组、GnRH-a治疗组的病理缓解率分别为70.5%和60.9%(P=0.197)。口服孕激素治疗组患者出现的不良反应主要包括体重增加(59.1%)、突破性出血(22.7%)、恶心呕吐(13.6%)及头晕乏力(6.8%)。GnRH-a治疗组患者出现的不良反应主要包括潮热(67.4%)、阴道干燥(34.8%)、精神状态改变(32.6%)、头痛乏力(10.9%)。患者均未出现血栓形成及肝酶升高。结论:对50岁以下的CH患者,可首选宫腔内置入LNG-IUS系统。对AH患者,若无生育要求或手术禁忌证,应首选手术治疗;对于50岁以下选择保守治疗的患者,口服孕激素和GnRH-a治疗的疗效相当。保守治疗需在严格监测下进行,以便及时发现癌变。
关键词(KeyWords)： 子宫内膜增殖症;治疗;孕激素;口服避孕药;LNG-IUS;GnRH-a
基金项目(Foundation): 卫生行业科研专项(No:201002013)
作者(Authors): 孙清;杨兴升;李玲;何淼龙;吴倩;王秀珍;
DOI: 10.13283/j.cnki.xdfckjz.2014.06.003
参考文献(References)：
- [1]Kurman RJ,Kaminsk PF,Norris HJ.The behavior of endometrial hyperplasia.A long-term study of"untreated"hyperplasia in 170 patients.[J].Cancer,1985,56:403-412
- [2]Trimble CL,Kauderer J,Zaino R,et al.Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia:a Gynecologic Oncology Group study.[J].Cancer,2006,106(4):812-819
- [3]Karamursel BS,Guven S,Tulunay G,et al.Which surgical procedure for patients with atypical endometrial hyperplasia?[J].Int J Gynecol Cancer,2005,15(1):127-131
- [4]Tavassoli FA,Devilee P.Pathology&genetics:tumours of the breast and female genital organs[M].Iarc,2003,4
- [5]Montgomery BE,Daum GS,Dunton CJ.Endometrial hyperplasia:A review[J].Obstet Gynecol Surey,2004,59(5):368-378
- [6]Terakawa N,Kigawa J,Taketani Y,et al.The Behavior of Endometrial Hyperplasia:A Prospective Study[J].J Obstet Gynaecol Res,1997,23(3):223-230
- [7]Tabata T,Yamawaki T,Yabana T,et al.Natural history of endometrial hyperplasia[J].Arch Gynecol Obstet,2001,265(2):85-88
- [8]Nilsson CG,Haukkamaa M,Vierola H,et al.Tissue concertrations of levonorgestrel in women using a levonorgestrel-releasing IUD[J].Clin Endocrinol,1982,17(6):529-536
- [9]Grimbizis G,Tsalikis T,Tzioufa V,et al.Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin:a prospective study[J].Hum Reprod,1999,14(2):479-484
- [10]Buttini MJ,Jordan SJ,Webb PM.The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia:An Australian study and systematic review[J].Aust Nz J Obstet Gynecol,2009,49(3):316-322
- [11]Gallos ID,Shehmar M,Thangaratinam S,et al.Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia:a systematic review and metaanalysis[J].Am J Obstet Gynecol,2010,203(6):547.e1-547.e10
- [12]Gallos ID,Krishan P,Shehmar M,et al.LNG-IUS versus oral progestogen treatment for endometrial hyperplasia:a long-term comparative cohort study[J].Hum Reprod,2013,28(11):2966-2971
- [13]Agorastos T,Bontis J,Vakiani A,et al.Treatment of Endometrial Hyperplasias with Gonadotropin-Releasing Hormone Agonists:Pathological,Clinical,Morphometric,and DNA-Cytometric Data[J].Gynecol Oncol,1997,65(1):102-114
- [14]梁秀兰,阮祥燕.子宫内膜增生的内分泌治疗进展[J].中国处方药,2009,3(1):65-68,71
- [15]魏晓丽,周远征,孙爱军,等.孕激素治疗子宫内膜不典型增生患者的剂量选择[J].基础医学与临床,2010,12(6):658-661
- [16]Ramirez PT,Frumovitz M,Bodurka DC,et al.Hormonal therapy for the management of grade 1 endometrial adenocarcinoma:a literature review[J].Gynecol Oncol,2004,95(1):133-138
- [17]Niwa K,Tagami K,Lian Z,et al.Outcome of fertility-preserving treatment in young women with endometrial carcinomas[J].BJOG-Int J Obstet Gynecol,2005,112(3):317-320
- [18]俞梅,沈铿,杨佳欣,等.高分化子宫内膜样癌及子宫内膜重度不典型增生患者孕激素治疗的临床分析[J].中华妇产科杂志,2006,4:242-245